MSX-122

· Metastatix, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for MSX-122, covering 2008-03-26 to 2008-03-26. Get the full timeline:

Most recent: Clinical Trial Update: MSX-122 Administered Orally in Patients With Refractory Metastatic or Locally Advanced Solid Tumors [Phase 1]